Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3144-3150

  Lorigan, Paul ^a   Verweij, Jaap ^a   Papai, Zsuzsa ^a   Rodenhuis, Sjoerd ^a   Le Cesne, Axel ^a   Leahy, Michael G ^a   Radford, John A ^a   Van Glabbeke, Martine M ^a   Kirkpatrick, Anne ^a   Hogendoorn, Pancras C W ^a   Blay, Jean Yves ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN DISEASE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORGANIZATION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547688913     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.7717     Document Type: Article

References (32)

1. Blay J, van Glabbeke M, Verweij J, et al: Advanced soft tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39:64-69, 2003
2. Van Glabbeke M, van Oostroom A, Oosterhuis J, et al: Prognostic factors for the ourcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first line regimens- an EORTC Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17: 150-157, 1999
3. O'Sullivan B, Bell R, Bramwell V: Sarcoma of the soft tissues, in Souhami RL, Tannock I, Hohenberger P, et al (eds): Oxford Text Book of Oncology (ed 2). New York, Oxford University Press, 2002, pp 2495-2523
4. Lopez M, Vici P, Di Lauro L, et al: Increasing single epirubicin dose in advanced soft tissue sarcoma. J Clin Oncol 20:1329-1334, 2002
5. Nielsen O, Dombernowsky P, Mouridsen H, et al: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78:1634-1639, 1998
6. Judson I, Radford J, Harris M, et al: Randomised phase II trial of pegylated liposomal doxorubicin (Doxil, Caelyx) versus doxorubicin in advanced or metastatic STS: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877, 2001
7. Benjamin R, Legha S, Patel S, et al: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The MD Anderson experience. Cancer Chemother Pharmacol 31:S174-S179, 1993
8. Patel S, Vadhan-Raj S, Papadopolous N, et al: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies-dose response and schedule dependence. J Clin Oncol 15:2378-2384, 1997
9. Van Oosterom A, Mouriden H, Nielsen O, et al: Results of a randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
10. Nielsen O, Judson I, van Hoesel Q, et al: Effects of high-dose ifosfamide in advanced soft tissue sarcoma: A multicentre phase II study of the EORTC Soft tissue and Bone sarcoma Group. Eur J Cancer 36:61-67, 2000
11. Chang P, Wiernick P: Combination chemotherapy with doxorubicin and streptozocin: Clinical results in patients with advanced sarcoma. Clin Pharmacol Ther 20:60-610, 1976
12. Omura G, Major F, Blessing A, et al: A randomised study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcoma. Cancer 52:626-632, 1983
13. Muss H, Bundy B, DiSaia J, et al: Treatment of recurrent or advanced uterine sarcoma: A randomised trial of doxorubicin versus doxorubicin and cyclophosphamide - A phase III trial of the Gynaecologic Oncology Group. Cancer 55:1648-1653, 1985
14. Schoenfeld D, Rosenbaum C, Horon J, et al: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide, versus vincristine, actinomycin D and cyclophosphamide for advanced sarcoma. Cancer 50:2757-2762, 1982
15. Borden E, Amato D, Edmonson J, et al: Randomised comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcoma. Cancer 66:862-867, 1990
16. Borden E, Amato D, Rosenbaum C, et al: Randomised comparison of three adriamycin regimens for soft tissue sarcoma. J Clin Oncol 5:840-850, 1987
17. Edmonson JH, Ryan LM, Blum R H, et al: Randomised comparison of doxorubicin alone versus ifosfomide plus doxorubicin or mitomycin, doxorubicin and cisplatin in advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
18. Santoro A, Trez T, Mourisden H, et al: Doxorubicin versus CYVADIC versus Doxorubicin plus Ifosfomide in first line treatment for soft tissue sarcoma: A randomised study of the European Organisation for the Research and Treatment of Cancer. J Clin Oncol 13:1537-1545, 1995
19. Bramwell V, Anderson D, Charette M: Doxorubicin-based chemotherapy for the palliative treatment of adults with locally advanced or metastatic soft tissue sarcoma. The Cochrane Database of Systematic Reviews 2:2007
20. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomised study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. J Clin Oncol 11:1276-1285, 1993
21. Baker L, Frank J, Fine G, et al: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide and actinomycin-D for advanced soft tissue sarcoma: A randomised comparative trial - A phase III Southwest Oncology Group Study (7613). J Clin Oncol 5:851-861, 1987
22. Pinedo H, Bramwell V, Mouridsen H, et al: CYVADIC in advanced soft tissue sarcomas: A randomised study comparing comparing 2 schedules. Cancer 53:1825-1832, 1984
23. Worden F, Taylor J, Biermann J, et al: Randomised phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor prognosis soft tissue sarcoma. J Clin Oncol 23:105-112, 2005
24. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumours: European Organisation for the Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Cancer. J Natl Cancer Inst 92:205-216, 2000
25. Arbuck SG, Ivy SP, Setser A, et al: The Revised Common Toxicity Criteria: Version 2.0. CTEP Web site. http://ctep.info.nih.gov
26. Le Cesne A, Judson I, Crowder D, et al: Randomised phase III study comparing conventional doxorubicin plus ifosfomide versus high dose doxorubicin plus ifosfomide plus recombinant human GCFS in advance soft tissue sarcoma: Trial of EORTC Soft Tissue and Bone sarcoma Group. J Clin Oncol 18:2676-2684, 2000
27. Blay JY, Bouhour D, Ray-Coquard I, et al: High dose chemotherapy with autologous haematopoietic stem cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18:3643-3650, 2000
28. Van Glabbeke M, Verweij J, Judson I, et al: Progression free rate as the principal endpoint for phase II trials in soft tissue sarcoma. Eur J Cancer 38:543-549, 2002
29. Fata F, O'Reilly E, Ilson D, et al: Paclitaxel in the treatment of patients with angiosarcoma of the face or scalp. Cancer 86:2034-2037, 1999
30. Skubitz KM, Haddad P: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104:361-366, 2005
31. Hensley M, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma, results of a phase II study. J Clin Oncol 20:2824-2831, 2002
32. Verweij J, Casali P, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004